Janssen first industrial partner to plug into Single Cell Accelerator

22 September 2018
VIB’s expertise in the single-cell field is also of great value for Biotech and Pharma, and long-term collaborations are being established in the Single Cell Accelerator (SCA). Janssen Pharmaceutica NV, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, is the first pharma partner in the SCA. Both VIB and Janssen Pharmaceutica are looking forward to this exciting collaboration.

Jérôme Van Biervliet, Head of Business Development VIB: “We have had a long-standing relationship of intense collaboration, strategic partnerships and scientific exchange with Janssen. The current collaboration now extends this tradition to another legacy of VIB – namely accessing emerging research technologies through our Tech Watch program. The Single Cell Accelerator will also accelerate industry-academia collaborations and leverage the expertise on both sides.”

Senior leadership team of Janssen R&D visits VIB 
The signing took place during a visit of the Senior Leadership Team of Janssen R&D to VIB last June. Senior Leaders from different research domains within Janssen R&D had the opportunity to meet with and get introduced into the research of Bart Lambrecht, Dirk Elewaut and Martin Guilliams from the VIB-UGent Center for Inflammation Research, Diether Lambrechts, Jan Cools and Gabriele Berger from the VIB-KU Leuven Center for Cancer Biology and Bart De Strooper from the VIB-KU Leuven Center for Brain & Disease Research, including existing collaborations with Frederik Stevenaert and Dieder Moechars from the Janssen campus in Beerse. A very inspiring meeting for all attendees.

Pieter Peeters, Sr Director, Computational Biology of Janssen Pharmaceutica: “The enthusiasm and passion for science is what made, and will continue to make, the collaborations between VIB and Janssen a success. I believe that the interaction between VIB PI’s and senior leaders at Janssen R&D has planted the seeds for more systematic interactions in the near future. We are very excited about our partnership with VIB’s Single Cell Accelerator and the opportunity it will provide us to enhance our ability to understand disease and mechanism of action of novel therapeutics”.

This new collaboration will help VIB and Janssen Pharmaceutica to combine forces to develop and evaluate emerging single-cell technologies, which will allow both parties to excel rapidly in the single-cell field. The newly developed methodologies will also be disseminated across the VIB centers to make an institute wide impact.

Go back to the overview 
   'Single Cell at ​​VIB'​

Johan Cardoen and Stef Heylen (COO Janssen R&D and Managing Director Janssen Pharmaceutica)​
© VIB-Ine Dehandschutter